FDG-PET/CT for Monitoring Response of Melanoma to the Novel Oncolytic Viral Therapy Talimogene Laherparepvec

Matthew F. Covington, Clara N Curiel, Lois Lattimore, Ryan J. Avery, Phillip H Kuo

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

61-year-old woman with stage IIIa (T3a N1a M0) left lower leg melanoma with lesions suggestive of in-transit metastases 8 months following wide local excision and femoral nodal dissection. FDG-PET/CT demonstrated 5 FDG-avid in-transit nodal metastases in the distal left leg, confirmed on biopsy. Talimogene laherparepvec (T-VEC) oncolytic immunotherapy consisting of intralesional injections of modified herpes simplex virus-expressing granulocyte-macrophage colony-stimulating factor was completed over 6 months. Subsequent FDG-PET/CT demonstrated reduced or resolved FDG activity in the treated in-transit metastases and a new FDG-avid left thigh in-transit metastasis. FDG-PET/CT can monitor response to T-VEC and potentially other novel viral immunotherapies.

Original languageEnglish (US)
Pages (from-to)114-115
Number of pages2
JournalClinical Nuclear Medicine
Volume42
Issue number2
DOIs
StatePublished - Feb 1 2017

Keywords

  • IMLYGIC
  • immunotherapy
  • in-transit metastasis
  • melanoma
  • PET
  • T-VEC
  • talimogene laherparepvec

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'FDG-PET/CT for Monitoring Response of Melanoma to the Novel Oncolytic Viral Therapy Talimogene Laherparepvec'. Together they form a unique fingerprint.

  • Cite this